Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 171

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 171
---
.3 million, to €12.6 million for the year ended December 31, 2024, as compared to revenue from collaboration and licensing agreements of €51.9 million for the year ended December 31, 2023.

Revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca signed in April 2015 and October 2018, as well as the agreement signed with Sanofi in 2016 and 2022 and also with Takeda in 2023. Proceeds are recognized on the basis of the percentage of completion of the works performed by the Company under such agreements.

Revenue from collaboration and licensing agreements is set forth in the table below.

                                                                                                                                                                                  Year ended December 31,                
                                                                                                                                                                                                     2023          2024  
                                                                                                                                                                                           (in thousands)                
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Proceeds from collaboration and licensing agreements                                                                                                                                                                   
  of which monalizumab agreement - AstraZeneca                                                                                                                                                      9,499       € 4,404  
  of which Sanofi agreement 2016                                                                                                                                                                    2,000         4,000  
  of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program                       18,873           401  
  of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the option exercise                                                                   15,800         1,700  
  of which Takeda agreement 2023                                                                                                                                                                    4,553             —  
  Proceeds from collaboration and licensing agreements                                                                                                                                             50,725        10,505  
  Invoicing of research and development costs (IPH5201)                                                                                                                                             1,165         2,060  
  Others                                                                                                                                                                                               11            56  
  Revenue from collaboration and licensing agreements                                                                                                                                            € 51,901      € 12,622  

Proceeds related to monalizumab.

Revenues related to monalizumab result from the partial recognition of the $250.0 million non-refundable upfront payment and the $100.0 million milestone resulting from the exercise of the option received in June 2015 and October 201